Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia

COMMERCIAL concentrates of human antihemophilic factor (factor VIII) have been available for nearly 20 years and have resulted in dramatic changes in the treatment of classic hemophilia. Home therapy, surgical intervention, and prolonged treatment of hospitalized patients with hemophilia have all been facilitated by the availability of lyophilized factor VIII preparations. Although factor VIII concentrates have improved the ease and effectiveness of treatment, transfusion-associated complications have also increased. Patients with hemophilia have a high frequency of seropositivity for human immunodeficiency virus type 1 (HIV-1) and are at risk for the acquisition of the acquired immunodeficiency syndrome (AIDS). Most reports indicate . . .